Abstract:Expression of p21 has been shown to be up-regulated by the p53 tumor suppressor gene in vitro in response to DNA-damaging agents. However, p21 expression can be regulated independently of p53, and here we show that expression of p21 in various tissues during development and in the adult mouse occurs in the absence of p53 function. However, most tissues tested did require p53 for p21 induction following exposure of the whole animal to gamma irradiation. These results show that normal tissue expression of p21 to high levels is not dependent on p53 and confirm that induction of p21 by DNA-damaging agents does require p53. p21 is expressed upon differentiation of p53-deficient murine erythroleukemia (MEL) cells, and the kinetics of induction of p21 in this system suggest that it may be involved in the growth arrest that precedes terminal differentiation. The gene is up-regulated in mouse fibroblasts in response to serum restimulation but the kinetics and levels of induction differ between wild-type and mutant cells. Expression of p21 message following serum restimulation is superinducible by cycloheximide in wild-type but not in p53-deficient cells. The increases in p21 mRNA are reflected in changes in p21 protein levels. p21 expression also appears to be regulated at the post-transcriptional level because moderate increases in mRNA expression, during differentiation of MEL cells and upon serum restimulation of fibroblasts, are followed by large increases in protein levels. Regulation of the mouse p21 promoter by p53 depends on two critical p53-binding sites located 1.95 and 2.85 kb upstream from the transcriptional initiation site. The sequences mediating serum responsiveness of the promoter map to a region containing the proximal p53 site. p53 appears to play a critical role in p21 induction following DNA damage. Moreover, p21 can be regulated independently of p53 in several situations including during normal tissue development, following serum stimulation, and during cellular differentiation.

p21 in cancer: intricate networks and multiple activities

The Multifaceted p21 (Cip1/Waf1/CDKN1A) in Cell Differentiation, Migration and Cancer Therapy

p21: A Two-Faced Genome Guardian

p21 in Cancer Research

Examination of the expanding pathways for the regulation of p21 expression and activity

Inhibition of Cyclin-Dependent Kinases by P21.

CDK-Independent and PCNA-Dependent Functions of p21 in DNA Replication

P21 Disrupts the Interaction Between Cdk2 and the E2F-p130 Complex.

The p21 cyclin–dependent kinase inhibitor suppresses tumorigenicity in vivo

p21-containing cyclin kinases exist in both active and inactive states.

Inhibition of p21 activates Akt kinase to trigger ROS-induced autophagy and impacts on tumor growth rate

p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage.

Regulation of the cdk inhibitor p21 gene during cell cycle progression is under the control of the transcription factor E2F

Cell-cycle inhibition by independent CDK and PCNA binding domains in p21Cip1

P21(Cip1) Attenuates Ras- and C-Myc-Dependent Breast Tumor Epithelial Mesenchymal Transition and Cancer Stem Cell-Like Gene Expression in Vivo

P57: A Multifunctional Protein In Cancer (Review)

Pro-survival roles for p21(Cip1/Waf1) in Non-Small Cell Lung Cancer

Radiation-induced cell cycle arrest compromised by p21 deficiency

Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21WAF1/CiPl

p27 inhibits CDK6/CCND1 complex formation resulting in cell cycle arrest and inhibition of cell proliferation